Patients treated with metformin are at a lower risk of colorectal and liver cancers, compared to those receiving either insulin or sulphonylurea (Table 4), and at a lower risk of breast and lung cancer (Table 4), compared to those receiving sulphonylureas. This evidence concerns the gene INS and lung carcinoma.